var data={"title":"Duloxetine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Duloxetine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6083?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=duloxetine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Duloxetine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708710\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Suicidal thoughts and behavior:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. The studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients older than 24 years; there was a reduction in risk with antidepressant use in patients 65 years and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening and emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163737\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cymbalta;</li>\n      <li>Irenka [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5687669\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cymbalta;</li>\n      <li>Duloxetine DR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163755\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163740\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Major depressive disorder:</b> Oral: Initial: 40 to 60 mg daily; dose may be divided (ie, 20 or 30 mg twice daily) or given as a single daily dose of 60 mg. For some patients it may be desirable to start at 30 mg once daily for 1 week before increasing to 60 mg once daily. Maintenance: 60 mg once daily; doses up to 120 mg/day were studied in clinical trials but did not confer any additional benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic neuropathy: </b>Oral: Initial: 60 mg once daily; lower initial doses may be considered in patients where tolerability is a concern and/or renal impairment is present; maximum dose: 60 mg once daily; doses up to 120 mg/day were studied in clinical trials but did not confer any additional benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fibromyalgia (excluding Irenka):</b> Oral: Initial: 30 mg once daily for 1 week, then increase to 60 mg once daily as tolerated; maximum dose: 60 mg daily; doses up to 120 mg/day were studied in clinical trials but did not confer any additional benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Generalized anxiety disorder:</b> Oral: Initial: 60 mg once daily; for some patients it may be desirable to start at 30 mg once daily for 1 week before increasing to 60 mg once daily. For doses &gt;60 mg once daily, titrate dose in increments of 30 mg once daily over 1 week as tolerated; doses up to 120 mg/day were studied in clinical trials but did not confer any additional benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic musculoskeletal pain (includes patients with chronic low back pain or osteoarthritis of the knee):</b> Oral: Manufacturer's labeling: 30 mg once daily for 1 week, then increase to 60 mg once daily as tolerated; maximum dose: 60 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Osteoarthritis of the knee (off-label dose):</i> Initial: 30 mg once daily for 1 week, then 60 mg once daily; may further increase to 120 mg once daily (dose was increased after week 2 or 6 weeks in trials); effective dosage range studied: 60 to 120 mg once daily; maximum dose: 120 mg/day (Wang 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Stress urinary incontinence (women) (off-label use):</b> Oral: 40 mg twice daily (Li 2013). Lower initial doses have been used to reduce adverse effects: 20 mg twice daily for 2 weeks titrated to or followed by 40 mg twice daily (Castro-Diaz 2007; Schagen van Leeuwen 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporting ideal taper rates is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. In addition for long-term treated patients, WFSBP guidelines recommend tapering over 4 to 6 months. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (APA 2010; Bauer 2002; Haddad 2001; NCCMH 2010; Schatzberg 2006; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>MAO inhibitor recommendations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Switching to or from an MAO inhibitor intended to treat psychiatric disorders:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of duloxetine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allow &ge;5 to 14 days to elapse between discontinuing duloxetine and initiation of an MAO inhibitor intended to treat psychiatric disorders.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26343591\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Generalized anxiety disorder: </b>Children and Adolescents 7 to 17 years: Oral: Initial: 30 mg once daily; after 2 weeks may increase based on response and tolerability to 60 mg once daily; titrate doses &gt;60 mg once daily in increments of 30 mg once daily; maximum dose: 120 mg once daily.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163741\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Generalized anxiety disorder:</b> Oral: Initial: 30 mg once daily; after 2 weeks may increase to 60 mg once daily; titrate doses &gt;60 mg once daily in increments of 30 mg once daily; maximum dose: 120 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Other indications:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Discontinuation of therapy:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>MAO inhibitor recommendations:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163742\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however pharmacokinetic studies suggest that mild to moderate renal impairment (CrCl 30 to 80 mL/minute) has no significant effect on duloxetine clearance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: Avoid use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease (ESRD): Avoid use</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163743\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid use in hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163711\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release Particles, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cymbalta: 20 mg, 30 mg, 60 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Irenka: 40 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 30 mg, 40 mg, 60 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163696\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874615\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088579.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlwuzDsEGIBO8Tjw0asbi2Cg==&amp;TOPIC_ID=8484\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088579.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163715\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Swallow capsule whole; do not crush or chew. Although the manufacturer does not recommend opening the capsule to facilitate administration, duloxetine has been found to be stable for up to 2 hours after sprinkling the contents of capsule on applesauce or in apple juice (not chocolate pudding) taking care not to crush the pellets and damage the enteric coating (Wells, 2008). Tolerability studies of this administration technique have not been conducted. Adverse effects have been reported to the FDA when patients opened the capsules, however, reports do not detail if pellets were crushed (FDA, 2007).  Administer without regard to meals. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163714\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic musculoskeletal pain:</b> Management of chronic musculoskeletal pain.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic peripheral neuropathic pain:</b> Management of diabetic peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fibromyalgia (except Irenka):</b> Management of fibromyalgia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Generalized anxiety disorder:</b> Treatment of generalized anxiety disorder (GAD).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Major depressive disorder:</b> Treatment of major depressive disorder (MDD).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725306\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Stress urinary incontinence (women)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163762\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cymbalta may be confused with Symbyax</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">DULoxetine may be confused with FLUoxetine, vortioxetine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to its potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163702\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (13% to 14%), drowsiness (9% to 11%; dose related), fatigue (7% to 11%; dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (18% to 23%), xerostomia (adults: 11% to 14%; dose related, children and adolescents: 2%), abdominal pain (children and adolescents: 13%, adults: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (children and adolescents: 14%, adults: &ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (&le;7% to &le;11%; dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (3%), increased blood pressure (2%), palpitations (&ge;1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (7% to 10%; dose related), dizziness (8% to 9%), agitation (3% to 4%), anxiety (3%), delayed ejaculation (2%; dose related), yawning (&ge;1% to 2%), abnormal dreams (&ge;1%), anorgasmia (&ge;1%), chills (&ge;1%), hypoesthesia (&ge;1%), lethargy (&ge;1%), paresthesia (&ge;1%), rigors (&ge;1%), sleep disorder (&ge;1%), vertigo (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (6%), pruritus (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased libido (3%), orgasm abnormal (&ge;1% to 2%), hot flash (&ge;1%), weight gain (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (9% to 10%; dose related), decreased appetite (6% to 10%; dose related), vomiting (children and adolescents: 9%; adults: 3% to 4%), diarrhea (6% to 9%), dyspepsia (2%), dysgeusia (&ge;1%), flatulence (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Erectile dysfunction (4%), ejaculatory disorder (2%), urinary frequency (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&gt;3 x ULN: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (2% to 3%; dose related), musculoskeletal pain (&ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (&ge;1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Oropharyngeal pain (children and adolescents: 4%; adults: &ge;1%), cough (children and adolescents: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, acute pancreatitis, aggressive behavior (particularly early in treatment or after treatment discontinuation), akathisia, anaphylaxis, angioedema, angle-closure glaucoma, apathy, bruxism, cardiomyopathy (takotsubo), cholestatic jaundice, cold extremities, confusion, contact dermatitis, dehydration, diplopia, disorientation, disturbance in attention, dry eye syndrome, dysarthria, dyskinesia, dyslipidemia, dysphagia, dysuria, ecchymoses, elevated glycosylated hemoglobin (diabetic neuropathic pain), emotional lability, epistaxis, eructation, erythema, erythema multiforme, extrapyramidal reaction, falling, feeling abnormal, galactorrhea, gastric ulcer, gastritis, gastroenteritis, gastrointestinal hemorrhage, gynecological bleeding, halitosis, hallucination, hematoma, hepatic failure, hepatitis, hepatomegaly, hostility, hyperbilirubinemia, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperlipidemia, hyperprolactinemia, hypersensitivity angiitis, hypersensitivity reaction, hypertensive crisis, hypertonia, hypokalemia, hypomania, hyponatremia, hypothyroidism, impulsivity, increased blood pressure, increased creatine phosphokinase, increased diastolic blood pressure, increased serum alkaline phosphatase, increased serum AST, increased serum bicarbonate, increased serum transaminases, increased thirst, irritability, jaundice, laryngitis, lymphocytic colitis, malaise, malodorous urine, mania, menopausal symptoms, menstrual disease, myocardial infarction, muscle spasm, muscle twitching, myoclonus, night sweats, nocturia, orthostatic hypotension, otalgia, outbursts of anger (particularly early in treatment or after treatment discontinuation), panic attack, petechia, pharyngeal edema, polyuria, restless leg syndrome, seizure, sensation of cold, serotonin syndrome, sexual disorder, SIADH, skin photosensitivity, skin rash, Stevens-Johnson syndrome, stomatitis, suicidal ideation, supraventricular cardiac arrhythmia, syncope, tachycardia, testicular pain, tinnitus, trismus, urinary retention, urinary urgency, urticaria, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163718\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use of monoamine oxidase (MAO) inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing the MAO inhibitor); initiation of MAO inhibitor intended to treat psychiatric disorders within 5 days of discontinuing duloxetine; initiation of duloxetine in a patient receiving linezolid or intravenous methylene blue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to duloxetine or any component of the formulation; hepatic impairment; severe renal impairment (eg, CrCl &lt;30 mL/minute) or end-stage renal disease (ESRD); uncontrolled narrow-angle glaucoma; concomitant use with thioridazine or with potent CYP1A2 inhibitors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163700\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Major psychiatric warnings:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal thinking/behavior: <b>[US Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18 to 24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;</b> consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient's family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants in children and teenagers should be dispensed with each prescription.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their health care provider if any of these symptoms or worsening depression occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin or NSAIDs due to ulcerogenic potential. Bleeding related to SNRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic: Severe skin reactions (including Stevens-Johnson syndrome and erythema multiforme) have been reported; discontinue immediately if blisters, peeling rash, mucosal erosions, or any other signs of hypersensitivity reactions are suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Bone fractures have been associated with antidepressant treatment. Consider the possibility of a fragility fracture if an antidepressant-treated patient presents with unexplained bone pain, point tenderness, swelling, or bruising (Rabenda 2013; Rizzoli 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Avoid use in patients with substantial ethanol intake, evidence of liver disease or hepatic impairment. Rare cases of hepatic failure (including fatalities) have been reported with use. Hepatitis with abdominal pain, hepatomegaly, elevated transaminase levels &gt;20 times the upper limit of normal (ULN) with and without jaundice have all been observed. Discontinue therapy with the presentation of jaundice or other signs of hepatic dysfunction and do not reinitiate therapy unless another source or cause is identified.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Modest increases in serum glucose and hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) levels have been observed in some diabetic patients receiving duloxetine for diabetic peripheral neuropathic pain (DPNP).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: May cause mild pupillary dilation which in susceptible individuals can lead to an episode of narrow-angle glaucoma. Consider evaluating patients who have not had an iridectomy for narrow-angle glaucoma risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension/syncope: May cause orthostatic hypotension/syncope, especially within the first week of therapy and after dose increases. Carefully monitor blood pressure with initiation of therapy, dose increases (especially in patients receiving &gt;60 mg/day), or when using concomitant vasodilators or CYP1A2 inhibitors. Consider dose reduction or discontinuation of duloxetine if orthostatic hypotension or syncope occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome (SS) reactions: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St John's wort) or drugs that impair serotonin metabolism (eg, MAO inhibitors, specifically linezolid, methylene blue, and others used for psychiatric disorders). Monitor patients closely for signs/symptoms of SS which may include mental status changes (eg, agitation, hallucinations, delirium), seizures, autonomic instability (eg, tachycardia, dizziness, diaphoresis), neuromuscular symptoms (eg, tremor, rigidity, myoclonus), or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea). Discontinue treatment (and any concomitant serotonergic agents) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L), predominately in the elderly. Volume depletion and/or concurrent use of diuretics likely increases risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary hesitancy: May cause increased urinary resistance; advise patient to report symptoms of urinary hesitation/difficulty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastroparesis: Use caution in patients with impaired gastric motility (eg, some diabetics); may affect stability of the capsule's enteric coating.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Avoid use in patients with chronic liver disease or cirrhosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Use caution in patients with hypertension. Although no statistically significant differences in the frequency of sustained elevations of blood pressure were observed in clinical trials when compared with placebo, modest increases in blood pressure have been reported with use. Additionally, rare cases of hypertensive crisis have been reported; blood pressure should be evaluated prior to initiating therapy and periodically thereafter; consider dose reduction or gradual discontinuation of therapy in individuals with sustained hypertension during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mania/hypomania: May precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder. <b>Duloxetine is not FDA approved for the treatment of bipolar depression.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; clearance is decreased and plasma concentrations are increased; avoid use in patients with CrCl &lt;30 mL/minute or ESRD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism (Montgomery 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fall risk: Falls with serious consequences including bone fractures and hospitalization have been reported in patients receiving therapeutic doses of duloxetine. The risk of falling appears related to the degree of orthostatic decrease in blood pressure. Risks may also be greater in elderly patients, patients taking concomitant medications that induce orthostatic hypotension or are potent CYP1A2 inhibitors, and in patients taking doses &gt;60 mg/day. Consider dose reduction or discontinuation of duloxetine if falls occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sucrose intolerance: Some formulations may contain sucrose; patients with fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency should avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation syndrome: Abrupt discontinuation or interruption of antidepressant therapy has been associated with a discontinuation syndrome. Symptoms arising may vary with antidepressant however commonly include nausea, vomiting, diarrhea, headaches, lightheadedness, dizziness, diminished appetite, sweating, chills, tremors, paresthesias, fatigue, somnolence, and sleep disturbances (eg, vivid dreams, insomnia). Less common symptoms include electric shock-like sensations, cardiac arrhythmias (more common with tricyclic antidepressants), myalgias, parkinsonism, arthralgias, and balance difficulties. Psychological symptoms may also emerge such as agitation, anxiety, akathisia, panic attacks, irritability, aggressiveness, worsening of mood, dysphoria, mood lability, hyperactivity, mania/hypomania, depersonalization, decreased concentration, slowed thinking, confusion, and memory or concentration difficulties. Greater risks for developing a discontinuation syndrome have been associated with antidepressants with shorter half-lives, longer durations of treatment, and abrupt discontinuation. For antidepressants of short or intermediate half-lives, symptoms may emerge within 2 to 5 days after treatment discontinuation and last 7 to 14 days (APA 2010; Fava 2006; Haddad 2001; Shelton 2001; Warner 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163748\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163704\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8484&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Specifically, risks of psychomotor impairment may be enhanced. Alcohol (Ethyl) may enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran. Management: Patients receiving serotonin/norepinephrine reuptake inhibitors (SNRIs) should be advised to avoid alcohol.  Monitor for increased psychomotor impairment and hepatotoxicity in patients who consume alcohol during treatment with SNRIs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the antihypertensive effect of Alpha2-Agonists. <b> Exceptions: </b>Apraclonidine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: May enhance the adverse/toxic effect of DULoxetine. ARIPiprazole may enhance the serotonergic effect of DULoxetine. This could result in serotonin syndrome. DULoxetine may increase the serum concentration of ARIPiprazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of DULoxetine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May increase the serum concentration of DULoxetine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May increase the serum concentration of DULoxetine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Substrates (High risk with Inhibitors): CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Tamoxifen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP2D6 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce the eliglustat dose to 84 mg daily. Avoid use of eliglustat in combination with a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with serotonin/norepinephrine reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.  Management: Consider an alternative for one of the interacting drugs in order to avoid metoprolol toxicity. If the combination must be used, monitor response to metoprolol closely. Metoprolol dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.  While methylene blue and linezolid are expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Methylene Blue; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PARoxetine: DULoxetine may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of DULoxetine.  Management: Coadminister with caution.  If duloxetine and paroxetine are used in combination, monitor for signs and symptoms of serotonin toxicity/serotonin syndrome, as well as other toxic effects of duloxetine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors may increase the serum concentration of Perhexiline.  Management: Consider alternatives to this combination if possible. If combined, monitor for increased perhexiline serum concentrations and toxicities (eg, hypoglycemia, neuropathy, liver dysfunction). Perhexiline dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thioridazine: CYP2D6 Inhibitors may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: DULoxetine may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. DULoxetine may decrease the metabolism of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163706\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163721\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hyper- or hypotonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SNRIs/SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. The long-term effects of in utero SNRI/SSRI exposure on infant development and behavior are not known.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women exposed to duloxetine during pregnancy in the Cymbalta Pregnancy Registry (866-814-6975 or http://cymbaltapregnancyregistry.com).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Women 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163722\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duloxetine is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The relative infant dose (RID) of duloxetine is 2.3% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 60 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000). However some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The RID of duloxetine was calculated using a milk concentration of ~120 mcg/L, providing an estimated daily infant dose via breast milk of 0.02 mg/kg/day. This milk concentration was obtained following maternal administration of duloxetine 60 mg/day (Briggs 2009). Duloxetine has also been detected in the serum of a breastfeeding infant (Boyce 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Information related to the use of duloxetine in breastfeeding women is limited. Infants of mothers using psychotropic medications should be monitored daily for changes in sleep, feeding patterns, and behavior (Bauer 2013) as well as infant growth and neurodevelopment (Sachs 2013; Sriraman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The manufacturer recommends that caution be exercised when administering duloxetine to breastfeeding women. When first initiating an antidepressant in a breastfeeding woman, agents other than duloxetine are preferred. Women successfully treated with duloxetine during pregnancy may continue use while breastfeeding if there are no other contraindications (Berle 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163708\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure should be checked prior to initiating therapy and then regularly monitored, especially in patients with a high baseline blood pressure; mental status for depression, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased), anxiety, social functioning, mania, panic attacks or other unusual changes in behavior; glucose levels and HbA<sub>1c</sub> levels in diabetic patients, creatinine, BUN, transaminases</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163699\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a weak inhibitor of dopamine reuptake. Duloxetine has no significant activity for muscarinic cholinergic, H<sub>1</sub>-histaminergic, or alpha<sub>2</sub>-adrenergic receptors. Duloxetine does not possess MAO-inhibitory activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163717\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed, 2-hour delay in absorption after ingestion; food decreases extent of absorption ~10% (no effect on C<sub>max</sub>) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: ~1,640 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;90%; primarily to albumin and alpha<sub>1</sub>-acid glycoprotein</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, via CYP1A2 and CYP2D6; forms multiple metabolites (inactive) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~12 hours (range: 8 to 17 hours); ~4 hours longer in elderly women </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 6 hours; 10 hours when ingested with food </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~70%; &lt;1% of total dose as unchanged drug); feces (~20%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163720\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, enteric pellets</b> (Cymbalta Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $512.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $287.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (30): $287.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, enteric pellets</b> (DULoxetine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $419.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $235.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $235.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (30): $235.55</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539848\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alacir (CR, DO, GT, HN, NI, PA, SV, UY);</li>\n      <li>Ambidext (LK);</li>\n      <li>Andepra (AU);</li>\n      <li>Ariclaim (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, PL, PT, RO, RU, SE, SK, TR);</li>\n      <li>Aritavi (CZ, IE);</li>\n      <li>Cicleno (CL);</li>\n      <li>Cimal (CO);</li>\n      <li>Clonia (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cymbalta (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GT, HK, HN, HR, HU, ID, IE, IL, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, QA, RO, RU, SA, SE, SG, SK, TH, TR, TW);</li>\n      <li>Dalaful (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Delok (IN);</li>\n      <li>Deloxi (BD);</li>\n      <li>Doxet (PE);</li>\n      <li>Dulan (LK);</li>\n      <li>Duloprex (KR);</li>\n      <li>Dulox (BD);</li>\n      <li>Duloxa (KR);</li>\n      <li>Duloxeteg (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Dulsevir (LV);</li>\n      <li>Duroceptol (KR);</li>\n      <li>Duseta (KR);</li>\n      <li>Duxela (KR);</li>\n      <li>Duxetin (AR, UY);</li>\n      <li>Duxetine (TW);</li>\n      <li>Duxtin (BD);</li>\n      <li>Inmox (CO);</li>\n      <li>Loxentia (IE);</li>\n      <li>Lyta (LK);</li>\n      <li>Nitidex (AR);</li>\n      <li>Psynil (PH);</li>\n      <li>Sebata (KR);</li>\n      <li>Symbalta (UA);</li>\n      <li>Xeristar (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, HR, IE, IT, MT, NL, NO, RO, RU, SE, SK, TR);</li>\n      <li>Xinolax DR (BD);</li>\n      <li>Yentreve (AE, AT, BE, BG, CH, CL, CZ, DE, DK, EE, FI, FR, GB, HR, IE, IL, IT, LU, MT, MX, NL, NO, NZ, PL, RU, SE, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007), &ldquo;Use of Psychiatric Medications During Pregnancy and Lactation,&rdquo; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder, third edition. May 2010. Available at http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/12479080/pubmed\" target=\"_blank\" id=\"12479080\">12479080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/22299006/pubmed\" target=\"_blank\" id=\"22299006\">22299006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyce PM, Hackett LP, and Ilett KF, &quot;Duloxetine Transfer Across the Placenta During Pregnancy and Into Milk During Lactation,&quot; <i>Arch Womens Ment Health</i>, 2011, 14(2):169-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/21359876/pubmed\" target=\"_blank\" id=\"21359876\">21359876</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Briggs GG, Ambrose PJ, Ilett KF, et al, &quot;Use of Duloxetine in Pregnancy and Lactation,&quot; <i>Ann Pharmacother</i>, 2009, 43(11):1898-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/19809008/pubmed\" target=\"_blank\" id=\"19809008\">19809008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Castro-Diaz D, Palma PC, Bouchard C, et al; Duloxetine Dose Escalation Study Group. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. <i>Int Urogynecol J Pelvic Floor Dysfunct</i>. 2007;18(8):919-929.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/17160693/pubmed\" target=\"_blank\" id=\"17160693\">17160693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo; <i>N Engl J Med</i>, 2006, 354(6):579-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/16467545/pubmed\" target=\"_blank\" id=\"16467545\">16467545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cymbalta (duloxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cymbalta (duloxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cymbalta (duloxetine) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):14-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/16683858/pubmed\" target=\"_blank\" id=\"16683858\">16683858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration. DMETS Medication Error Postmarketing Safety Review. <a href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103473.pdf\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103473.pdf</a>. Published March 8, 2007. Accessed February 2, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/11347722/pubmed\" target=\"_blank\" id=\"11347722\">11347722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Irenka (duloxetine) [prescribing information]. Baltimore, Maryland: Lupin Pharma; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li J, Yang L, Pu C, Tang Y, Yun H, Han P. The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis. <i>Int Urol Nephrol</i>. 2013;45(3):679-686.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/23504618/pubmed\" target=\"_blank\" id=\"23504618\">23504618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mariappan P, Ballantyne Z, N'Dow JM, Alhasso AA. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults.<i> Cochrane Database Syst Rev</i>. 2005;(3):CD004742.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/16034945/pubmed\" target=\"_blank\" id=\"16034945\">16034945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications.<i> Int J Clin Pract</i>. 2005; 59(12):1435-1440.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/16351676/pubmed\" target=\"_blank\" id=\"16351676\">16351676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/22132433/pubmed\" target=\"_blank\" id=\"22132433\">22132433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. <i>J Am Geriatr Soc</i>. 2011;59(4):577-585.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/21453380/pubmed\" target=\"_blank\" id=\"21453380\">21453380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo; <i>Am J Health Syst Pharm</i>, 2004, 61(9):899-912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/15156966/pubmed\" target=\"_blank\" id=\"15156966\">15156966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/22638709/pubmed\" target=\"_blank\" id=\"22638709\">22638709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/22659406/pubmed\" target=\"_blank\" id=\"22659406\">22659406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schagen van Leeuwen JH, Lange RR, Jonasson AF, Chen WJ, Viktrup L. Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. <i>Maturitas</i>. 2008;60(2):138-147.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/18547757/pubmed\" target=\"_blank\" id=\"18547757\">18547757</a>]</span><span class=\"doi\">10.1016/j.maturitas.2008.04.012</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/16683860/pubmed\" target=\"_blank\" id=\"16683860\">16683860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelton, RC. Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/15014601/pubmed\" target=\"_blank\" id=\"15014601\">15014601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sriraman NK, Melvin K, Meltzer-Brody S. ABM Clinical Protocol #18: Use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/26204124/pubmed\" target=\"_blank\" id=\"26204124\">26204124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang ZY, Shi SY, Li SJ, et al. Efficacy and Safety of Duloxetine on Osteoarthritis Knee Pain: A Meta-Analysis of Randomized Controlled Trials. <i>Pain Med</i>. 2015;16(7):1373-1385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/26176791/pubmed\" target=\"_blank\" id=\"26176791\">26176791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/16913164/pubmed\" target=\"_blank\" id=\"16913164\">16913164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wells KA and Losin WG, &ldquo;<i>In vitro</i> Stability, Potency, and Dissolution of Duloxetine Enteric-Coated Pellets After Exposure to Applesauce, Apple Juice, and Chocolate Pudding,&rdquo; <i>Clin Ther</i>, 2008, 30(7):1300-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/18691989/pubmed\" target=\"_blank\" id=\"18691989\">18691989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yonkers KA, Wisner KL, Stewart DE, et al, &ldquo;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&rdquo; <i>Obstet Gynecol</i>, 2009, 114(3):703-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/duloxetine-drug-information/abstract-text/19701065/pubmed\" target=\"_blank\" id=\"19701065\">19701065</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8484 Version 255.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708710\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F163737\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5687669\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F163755\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F163740\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F26343591\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F163741\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F163742\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F163743\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F163711\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F163696\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874615\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F163715\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F163714\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725306\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F163762\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F163702\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F163718\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F163700\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F163748\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F163704\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F163706\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F163721\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F163722\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F163708\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F163699\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F163717\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F163720\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539848\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8484|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=duloxetine-patient-drug-information\" class=\"drug drug_patient\">Duloxetine: Patient drug information</a></li></ul></div></div>","javascript":null}